PFI-1 (PF6405761) is a novel, highly potent and selective BET (bromodomain-containing protein) inhibitor with antineoplastic activity.

MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes.

I-BRD9 is a BRD9 specific inhibitor, identified by scientists at GlaxoSmithKline.

PLX51107 is a novel, potent and selective BET (Bromodomain and Extra-Terminal motif) inhibitor, also called BRD4 (bromodomain and extra terminal domain) inhibitor with Kd values of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; BRD4 is overexpressed in CLL […]

I-BET151 (also known as GSK-1210151A) is a novel, potent and selective BET (Bromodomain and extra terminal domain) inhibitor with anticancer activity.

GSK5959 is a novel, potent, selective and cell permeable BRPF1 (bromodomain and PHD finger-containing) bromodomain inhibitor with an IC50 of 80 nM.

Apabetalone (also known as RVX-208, RVX000222) is a novel and potent inhibitor of BET (Bromodomain and Extra-Terminal) bromodomain (BD) with potential anti-inflammatory activity and the potential to be used in the treatment of cardiovascular diseases.

INCB054329 is a novel potent and selective inhibitor of Bromodomain and extra-terminal (BET) protein.

Bromodomain inhibitor-8 is a novel and potent BET bromodomain inhibitor with the potential to be used in the treatment of autoimmune and inflammatory diseases.

Y06137 (Y0-6137; Y0 6137)is a novel and potent bromodomain BET inhibitor (Kd = 81 nM.) with potential anticancer activity.